Semax and Selank are regulatory peptides developed in Russia with decades of preclinical and clinical research behind them. This article explains how each works, what the evidence on neuroprotection and mood regulation reports, and their current regulatory standing in 2026. Nothing here is medical advice; neither compound is FDA-approved for therapeutic use.
Semax is a synthetic heptapeptide (7 amino acids) derived from the N-terminal fragment of adrenocorticotropic hormone (ACTH). Specifically, it is ACTH(4-7), meaning it contains amino acids 4 through 7 of the natural hormone. Despite this peptide origin, Semax does not significantly activate the ACTH receptor; instead, it acts through brain-derived neurotrophic factor (BDNF) upregulation and dopaminergic pathways in the central nervous system.
Selank is a synthetic tetrapeptide (4 amino acids) designed as a functional analog of the immunomodulatory peptide tuftsin. Rather than acting through BDNF, Selank is studied for its anxiolytic and stress-modulating effects, with proposed mechanisms involving monoamine and neuropeptide systems that regulate mood and stress resilience.
The most extensively studied mechanism for Semax involves increased brain-derived neurotrophic factor (BDNF) expression in the hippocampus and other regions crucial for memory and cognition. Preclinical findings include:
Selank is studied primarily for mood regulation and stress resilience. Preclinical and clinical findings include:
Researchers sometimes study Semax and Selank together to model a balanced cognitive enhancement with mood stabilization. The conceptual frame is: Semax drives BDNF-mediated neurotrophy and focus, while Selank provides anxiolytic support and stress resilience. As of 2026, published human trials of this combination do not exist; most evidence remains preclinical.
Both Semax and Selank are not FDA-approved for any therapeutic indication in the United States. However, their regulatory landscape shifted significantly in July 2026. On July 23–24, the FDA's Pharmacy Compounding Advisory Committee voted to recommend both Semax and Selank for inclusion in the FDA's 503A bulk-drug-substances list — a non-binding vote that, if finalized by the FDA, would allow U.S. compounding pharmacies to legally prepare these compounds for patients under a prescription.
That vote reflected decades of Russian clinical use and preclinical supporting evidence, but importantly, the FDA has not yet formally adopted the committee's recommendation. The final regulatory decision is pending.
We supply Semax and Selank individually to the research community — each HPLC-tested to 99% purity, with certificates of analysis on every batch, shipped from the USA, strictly for in-vitro laboratory use:
View Semax (p005) View Selank (p006) Browse all research compounds
Universe Peptide publishes research-focused education for the scientific community. Products are for laboratory research only. See more in our News & research updates.